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The objective of this study was to document the convulsant properties of thiocolchicoside in rats, and to characterise the
electroclinical pattern of epileptic seizures. Experiments were carried out in three groups of male Wistar rats: in group A,
thiocolchicoside was applied topically to the pia, or given by microinjection to the cerebral cortex (2µg/µl); in group B, the
drug was administered parenterally (6 mg/kg) to rats with minimal lesions of the dura and arachnoid membranes; in group
C, thiocolchicoside was administered parenterally (up to 12 mg/kg) to intact rats. In all animals, electroclinical activity was
continuously monitored for at least 3 hours after thiocolchicoside injection or application. In group A, electrographic and
behavioural activity of focal motor seizures occurred in 100% of animals, developing into a focal status epilepticus; in group B,
a multifocal epileptic pattern with secondary generalisation, clinically characterised by clonic or tonic–clonic seizures occurred
in 100% of animals, until a secondarily generalised convulsive status epilepticus; in group C, none of animals showed either
electrographic or behavioural seizure activity. Our study documents that thiocolchicoside has a powerful convulsant activity in
the rat, perhaps due to an antagonistic interaction of the compound with a cortical subtype of the GABAA receptor.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Thiocolchicoside is a semi-synthetic derivative of a
naturally occurring colchicoside, a colchicine ana-
logue, extensively used clinically in some countries
as central acting muscle-relaxant, anti-inflammatory
and analgesic (Fig. 1)1. Colchicine may induce ex-
perimental epileptic foci in animals (mice, rabbits
and rats)2, and its intracranial administration causes
generalised convulsions and death3. Our preliminary
experimental findings, presented previously as an
abstract4, and our recent clinical data5 indicate that
thiocolchicoside also has powerful convulsant activity
in animals and in humans; particularly, in neurological
patients with disruption of their blood–brain barrier
(BBB) and in patients with history of epilepsy5. In
this paper, we document the occurrence of focal and
secondarily generalised convulsive status epilepticus
in the rat following the administration of thiocochico-
side. In order to induce focal status epilepticus, this
drug was applied topically to the pia or given by
microinjection to the cerebral cortex. To induce a
secondarily generalised status epilepticus, it was ad-
ministered parenterally to rats with minimal lesions
of the dura and arachnoid membranes.
METHOD
Studies were performed under a protocol approved
by the Institutional Animal Care Committee. Male
rats, Wistar Morini strain, weighing 270–350 g (3–4
months of age), fasting for 12 hours before the experi-
ments, and kept at a room temperature for 22 ◦C, were
anaesthetised with ether or ketamine hydrochloride
(about 50 mg/kg, intraperitoneally), the head mounted
in a stereotactic apparatus. Animals were randomly
divided into three groups (groups A, B and C).
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Fig. 1: Structures of thiocolchicoside (I), colchicoside (II) and colchicine (III).
510 G. Sechi et al.
The rats of group A were further divided into two
subgroups: in the first, after ketamine anaesthesia, the
cerebral cortex was exposed by craniotomy, the dura
was removed and electrocorticographic (ECoG) pat-
terns recorded bipolarly by six silver-ball electrodes
applied to the pia in bilateral symmetrical position (the
reference electrode was a screw placed on the nasal
bone). Focal epileptic seizures were induced in the
exposed cortex (right or left) by application of a small
piece of Spongostan (2 mm× 2 mm), a sponge of fib-
rin soaked in a 2 mg/ml isotonic sodium chloride so-
lution of thiocolchicoside (15 animals). In the second
subgroup, focal seizures were induced by one intra-
cortical microinjection of thiocolchicoside dissolved
in saline (the injection volume used was 1µl and the
total amount of thiocolchicoside applied was 2µg),
near the recording electrodes (10 animals). In this lat-
ter subgroup, each animal underwent a tracheotomy
under ether anaesthesia, and was then immobilised
with gallamine and artificially ventilated. Novocaine
infiltration of all warmed edges and pressure points
was carefully carried out to minimise possible source
of pain.
In group B, after ketamine anaesthesia, thiocolchi-
coside dissolved in saline was administered either
into the peritoneum (i.p.), or intramuscularly (i.m.)
(6 mg/kg) to rats with minimal lesions of the dura
and arachnoid membranes. The lesions of these mem-
branes occurred during the insertion of the screw
electrodes into the skull, or during craniotomy. In
particular, the lesions made during the insertion of the
screw electrodes were four, in symmetrical positions
in the area of the frontoparietal cortex bilaterally.
The extent of the lesions induced by screw elec-
trodes or craniotomy was about 0.1 mm × 0.1 mm
and 2 mm× 2 mm, respectively. In preliminary exper-
iments, different amounts of thiocolchicoside were
injected i.p. or i.m. in rats of the same age and weight
in order to establish the necessary dose of the drug
needed to induce constant and reliable electroclinical
responses. Similarly, the extent of the lesions of dura
and arachnoid membranes needed to obtain constant
and reliable seizure activity was established in prelim-
inary experiments. The surface electroencephalogram
(EEG) was recorded from the cortical convexity ei-
ther by means of six screw electrodes inserted into
the skull in bilateral symmetrical positions (the refer-
ence electrode placed on the nasal bone) (15 animals)
or, when a wide craniotomy was performed, by using
six ball electrodes applied to the pial surface (the
reference electrode was a screw electrode placed on
the nasal bone) (10 animals). In some cases bipolar
concentric electrodes were stereotaxically implanted
into subcortical structures according to the atlas of
Paxinos and Watson6. The following structures were
explored: left basolateral amygdaloid nucleus anterior
(BLA) (referred to bregma: 2.8 mm posterior, 8.5 mm
ventral, 5.0 mm lateral to the midline) (five animals)
and gigantocellular proper mesencephalic reticular
formation (MRF-Gi) (referred to bregma: 10.8 mm
posterior, 9.5 mm lateral to the midline, 10 mm ven-
tral) (five animals).
In group C, thiocolchicoside dissolved in saline
was administered i.p. or i.m. to intact rats, at doses
of 6 mg/kg (five animals), 8 mg/kg (five animals)
and 12 mg/kg (five animals). The surface EEG was
recorded by means of six subcutaneous needle elec-
trodes inserted in bilateral symmetrical position (the
reference electrode was fixed on the pinna).
In all animals the exposed cortex was covered with
warmed paraffin oil at 37 ◦C. Body temperature was
maintained between 36.5 and 37.5 ◦C with a heating
pad. Both depth and surface electrodes were connected
to an EEG recording apparatus (OTE Biomedica). The
electrocardiogram was routinely monitored. All ani-
mals were continuously monitored for at least 3 hours
after the thiocolchicoside injection or application. At
least 10 minutes of basal ECoG or EEG recording was
made in each animal. The position of the depth elec-
trodes was checked. Data given are mean ± standard
deviation.
RESULTS
In group A, treated with focal cortical thiocolchico-
side, electrographic and behavioural seizure activity
occurred in 100% of animals. The latency to focal
spike activity was 3± 2 minutes following topical ap-
plication of the drug on the pial surface, and 2.0 ±
1 minute following one intracortical microinjection.
The frequency of spikes was 48 ± 20 minutes. Af-
ter about 60 minutes, spikes and polyspikes, intermin-
gled with both bursts of focal recruiting discharges of
1.5- to 3-second duration and intermittent ictal focal
seizures of several seconds duration occurred, accom-
panied by controlateral myoclonic jerks (Fig. 2). The
electrographic seizure activity was interrupted by a
near complete depression of cortical activity on ECoG.
This activity progressed into a focal status epilepticus
and lasted for at least 3 hours.
In group B, treated with parenteral thiocolchico-
side, a multifocal epileptic pattern with secondary
generalisation, clinically characterised by clonic or
tonic–clonic seizures occurred in 100% of animals.
The latency to first spike activity and to the first sec-
ondarily generalised seizure until a convulsive status
epilepticus developed was 3± 1 and 60± 10 minutes,
respectively. After thiocolchicoside injection, the
spikes rose from the opposite hemisphere in a com-
pletely asynchronous way for 2–4 minutes, since when
a progressive and rapid temporal alliance between
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Fig. 2: Development of focal epileptiform activity in the left rat neocortex, after topical application of a small piece of
Spongostan soaked in an isotonic solution of thiocolchicoside. (A)–(E ) respectively: basal recordings, 0.5, 1.5, 10 and
60 minutes after drug application; L, left. Vertical calibration 200µV; horizontal calibration 1 second.
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Fig. 3: Development of cortical epileptiform activity, until a secondary generalised seizure in a rat, with minimal lesions of dura
and arachnoid membranes, injected with 6 mg/kg thiocolchicoside. (A)–(E) respectively: basal recordings, 3, 5, 30 and
60 minutes after drug injection; L, left. Vertical calibration 200µV; horizontal calibration 1 second.
the epileptic activity of the two hemispheres was
observed, giving origin to a pseudogeneralised pat-
tern. The amplitude and frequency of spikes rapidly
increasing, up to 0.6 mV and 50/minute, respectively.
After about 1 hour, the epileptic potentials became
subcontinuous and characterised by spike trains un-
til ictal electroclinical generalised seizures mainly
clonic or, occasionally tonic–clonic, which lasted
20–180 seconds (Fig. 3). The interval of intermittent
generalised seizure activity was 60±20 minutes. This
activity lasted for at least 3–5 hours, and resulted in
death in about 5% of treated rats. Depth electrode
recordings initially showed no involvement of the ex-
plored structures. With an 8- to 15-minute delay, as to
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Fig. 4: Development of cortical epileptiform activity in a rat, with minimal lesions of dura and arachnoid membranes, injected
with 6 mg/kg thiocolchicoside. (A)–(D) respectively: basal recordings, 3, 5 and 20 minutes after drug injection. The paroxysmal
activity appears in MRF-Gi with 15-minute delay, as to cortex. MRF recordings are given in addition to cortical recordings. L,
left. Vertical calibration 200µV; horizontal calibration 1 second.
the cortex, paroxysmal activity appeared also in sub-
cortical structures, at first in BLA, then in MRF-Gi.
At this time, a high degree of synchrony of spiking
between the various structures was evident (Fig. 4).
In group C, at the doses tested, none of animals
showed either electrographic or behavioural seizure
activity.
DISCUSSION
Thiocolchicoside, colchicoside and colchicine share
the same benzo[α]heptalenic moiety, however, thio-
colchicoside differs from colchicoside and colchicine
by substitution of a methoxy group for a thiomethyl
group on ring A (Fig. 1)1. Structural analysis of
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these compounds reveals the need for at least a single
methoxy group on rings A and C for neurotoxicity
of colchicine2. This drug, indeed, binds to tubulin
and has been found to be a selective toxin for den-
tate granule cells in the hippocampus of rats2. The
concomitance of a methoxy group on rings A and
C, instead, does not seem necessary for the convul-
sant activity of colchicine2. Our data on the powerful
convulsant activity of thiocolchicoside (lacking a
methoxy group on ring A) agree with these findings.
Our study documents that thiocolchicoside given at
doses of 6–12 mg/kg is unable to induce, in intact
rats, any electrical or behavioural paroxysmal activity.
However, when this compound is applied topically to
the pia, given by microinjection to cerebral cortex, or
administered parenterally at doses of 6 mg/kg to rats
with minimal lesions of the dura and arachnoid mem-
branes, it displays within a few minutes, a powerful
convulsant activity.
The impermeability of the BBB to thiocolchicoside
is likely related to the dose used since in preclinical
studies1 it was noted that in mice, at doses of 20 mg/kg
of thiocolchicoside, some animals exhibited trembling
and died 40 minutes after dosing. The relative imper-
meability of the BBB to therapeutic doses of thio-
colchicoside may explain why the convulsant activity
of this drug in humans so far has not been recognised,
despite its extensive use in clinical practice for about
30 years5.
In our experiments, after topical microinjection,
thiocolchicoside was able to induce focal cortical
seizures in micromolar amounts and after a short la-
tent period, while after its parenteral administration,
cortical spikes occurred firstly before subcortical
structures. These findings, in our opinion, strongly
point to the forebrain, and more specifically the cor-
tex, as the likely site where thiocolchicoside-induced
seizures are initiated. The occurrence of the high-
est levels of specific thiocolchicoside binding in the
deep layers of the frontal cortex of the rat fits this
possibility7.
The mechanism of action of thiocolchicoside is
only partially understood. Previous studies suggested
that an agonistic interaction of thiocolchicoside with
spinal-strychnine-sensitive glycine receptors could
mediate its myorelaxant activity8; such interaction,
however, does not readily explain how it may induce
seizures5.
Recent studies have, instead, demonstrated the
presence of thiocolchicoside-specific binding sites in
the rat cerebral cortex and in spinal cord–brainstem9,
with a pharmacological profile indicating a prefer-
ential interaction of this compound with a cortical
subtype of the GABAA receptor9. This peculiar in-
teraction is suggested both by the different affinities
for the GABAA receptor agonists and antagonists,
and by the finding that neurosteroids modulate the
binding in cortical but not in spinal cord–brainstem
synaptic membranes9. In particular, at cortical level,
thiocolchicoside seems to recognise a subpopulation
of GABAA receptors, expressing low-affinity binding
sites for GABA9. Since the low-affinity recognition
site seems to be an antagonistic-preferring site7, this
finding may readily explain both the electrophysio-
logical results reported in this study and the powerful
convulsant activity of thiocolchicoside noticed in
humans5.
Another interesting finding concerns the potency of
strychnine in inhibiting thiocolchicoside binding, par-
ticularly in the cerebral cortex9, suggesting a probable
interaction of both compounds at the same binding
sites9 at cortical level. Strychnine, it has recently been
shown, may interact in the brain, at submicromolar
doses, with strychnine-sensitive glycine receptors,
GABAA receptors, as well as nicotinic acetylcholine
receptors8–10, which are homologous members of a
receptor superfamily11, 12.
Like strychnine, thiocolchicoside has been shown to
interact with GABAA receptors and strychnine-sensi-
tive glycine receptors8, 9. These latter receptors are
mainly represented in the spinal cord and brainstem13,
and might be involved in the myorelaxant activity
of thiocolchicoside8. GABAA receptors, instead, are
mainly represented in the cerebral cortex14, 15, and
may be involved both in the convulsant activity of thio-
colchicoside, and in spiking produced by strychnine
in the cortex16. In particular, the convulsant activity
of thiocolchicoside is likely to involve an overcom-
ing effect of thiocolchicoside antagonism at a subset
of GABAA receptors, on thiocolchicoside inhibitory
effects of allosteric activation of strychnine-sensitive
glycine receptors. The prevalence of GABAA recep-
tors in the cerebral cortex, with respect to strychnine-
sensitive glycine receptors, fits this possibility13–15.
According to Engel17, in epilepsy research the thio-
colchicoside model would be classified with the group
of ‘acute experimentally induced seizure models’,
which would be equivalent to reactive seizures in hu-
mans, or with the group of animal models of epileptic
seizures in nonepileptic animals reported by Löscher
in a recent review18. The electroclinical pattern was
consistent with an acute focal and secondarily gen-
eralised convulsive status epilepticus. In this model,
the occurrence of a minimally disrupted BBB par-
allels a condition that can be found frequently in
clinical practice (e.g. after head trauma), in which
it has been shown that thiocolchicoside may induce
epileptic seizures in humans, at very low doses5. In
comparison with similar models characterised in far
greater detail (e.g. those obtainable with bicuculline
or strychnine or kainate)17, 18, the thiocolchicoside
model shows the same reproducibility and consistency
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and a peculiar mechanism of action (i.e. an antago-
nistic interaction with a subset of GABAA receptors,
and an agonistic interaction with strychnine-sensitive
glycine receptors)7, 9. This model could have utility
in studies of the functional anatomy, neural networks
and neurochemical mechanisms involved in epilepsy
and epileptic seizures.
CONCLUSIONS
Our experimental data document that thiocolchico-
side has a powerful convulsant activity in the rat. The
mechanism by which this drug produces focal and
secondarily generalised convulsive status epilepticus
deserves further investigation. Moreover, our findings
confirm the data obtained in humans indicating that the
convulsant activity of thiocolchicoside occurs mainly
when there are minimal lesions of the dura and arach-
noid membranes.
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